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Background: Cancer is the result of a multistep process of genomic alterations, including mutations in key regulatory
proteins that result in loss of balanced gene expression and subsequent malignant transformation. Throughout the
various stages of colorectal carcinoma (CRC), complex genetic alterations occur, of which over-expression of growth
factors, such as vascular endothelial growth factor, fibroblast growth factor and platelet-derive growth factor and
their corresponding receptor tyrosine kinases, have been shown to correlate with invasiveness, tumor angiogenesis,
metastasis, recurrence, and poor prognosis of colorectal cancer. To evaluate the therapeutic effect, we combined
Dovitinib, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases with chemotherapeutic drug,
oxaliplatin in preclinical models of colon cancer.
Methods: Human colon cancer cells with different RAS-RAF mutation status (HCT-116, HT-29, SW-480, CaCO2 and
LS174T) were treated with a combination of Dovitinib and Oxaliplatin at low dosage followed by assays to investigate
the effect of the combination on cell proliferation, cell migration, cell apoptosis and signaling pathways involved in
molecular mechanism of drug(s). The antitumor effects of either of the drugs were compared to the combination using
human colon carcinoma cell line HT-29 xenograft model. Treated vs untreated tumor sections were also compared for
proliferation and angiogenesis markers by immunohistochemistry.
Results: The combination of dovitinib and oxaliplatin showed higher in vitro cytotoxicity in colon cell lines irrespective
of their RAS-RAF status as compared to either of the drugs alone. Simultaneous inhibition of MAP kinase and AKT
pathways and induction of apoptosis via activation of caspases 9/caspases 3 contributed to the synergistic effect of this
combination therapy. In the xenograft model, the combination showed a significantly higher antitumor activity.
Immunohistochemistry of post treatment tumors showed a significant decrease in proliferation and angiogenesis
as compared to either of the treatments alone.
Conclusions: This study demonstrates the synergistic antitumor activity of combination of dovitinib and oxaliplatin
against colon cancer with different RAS-RAF status. The combination also showed its antitumor efficacy in a multidrug
resistant phenotype xenograft model. This provides a basis for further investigation for its potential in clinical
setting for colorectal cancer.
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Colorectal cancer (CRC) is the third most common can-
cer in men (663,000 cases, 10.0% of the total) and the
second in women (571,000 cases, 9.4% of the total)
worldwide (Globocan, an international agency for re-
search on cancer). American cancer Society estimates
that in 2013, approximately 142,820 new cases of colo-
rectal cancer will be diagnosed with 50,830 (26,300 men
and 24,530 women) in United States alone. Overall, the
lifetime risk of developing colorectal cancer is about 1 in
20 (5.1%) [1,2]. A number of different drugs have shown
significant antitumor activity in CRC, including the sys-
temic drugs 5-fluorouracil (5-FU), irinotecan, oxaliplatin,
bevacizumab, cetuximab and panitumumab, and the oral
drug capecitabine. Different regimens of these drugs,
such as the FOLFOX (leucovorin, 5-FU and oxaliplatin),
FOLFIRI (leucovorin, 5-FU and irinotecan) and XELOX
(oxaliplatin and capecitabine), with or without a mono-
clonal antibody agent have shown improved outcomes in
CRC [3-10]. The efficacy of chemotherapy has reached a
plateau and a 5-year survival rate of patients with ad-
vanced CRC still remains < 8% [11] with the underlying
molecular basis still not clearly defined.
With the advancement of genomic technology and
availability of various genetic animal models, it has been
proposed that the progression of CRC is from cumula-
tive changes in key genes controlling cell proliferation,
apoptosis and invasion [12-17]. Abnormally high activa-
tion of multiple signaling pathways such as RAS-RAF,
and WNT/APC/β-Catenin has been demonstrated to be
required for initiation and progression of colorectal car-
cinoma [18-20]. Some of these pathways are regulated
by key enzymes known as tyrosine kinases which phos-
phorylate tyrosine residues in protein that are associated
with either transmembrane receptor-linked proteins or
non-receptor cytoplasmic proteins [21]. Activated forms
of these enzymes are known to increase tumor cell pro-
liferation and growth, induce antiapoptotic effects and
promote angiogenesis and metastasis [22]. In addition to
activation by growth factors, kinase activation by som-
atic mutations is also a common mechanism for tumori-
genesis [23]. Mutations in kRAS (31%) and BRAF (9.6%)
are both thought to occur early in colorectal carcinogen-
esis and are associated with significantly poor survival
[24,25]. Although majority studies show that these two
mutations are rarely observed together, a recent study in
Chinese patients with CRC showed approximately 25%
of the population harboring both kRAS and bRAF muta-
tions [26]. The presence of multiple mutations has al-
ways posed potential limitations to the inhibitors. Since
receptor tyrosine kinase activation initiates these effects,
they are the key targets for inhibitors [22,27]. The ma-
jority of currently available tyrosine kinase inhibitors has
provided a new approach for cancer therapy and has thepotential for avoiding some of the drawbacks of cytotoxic
chemotherapy [22]. Targeted agents have also offered an
opportunity to reverse chemotherapy resistance and en-
hance response in patients with localized or advanced can-
cer [28]. Along with holding a great promise, these
inhibitors have also posed drawbacks, being beneficial to
only certain subpopulations of patients and limiting resist-
ance in patients who initially responded [29-31].
Dovitinib, or TKI258 (4-amino-5-fluoro-3-[5-(4-methyl-
piperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2 (1H)-one;
formerly known as CHIR-258), is a small molecule adeno-
sine 5′-triphosphate–competitive inhibitor of class III, IV,
and V receptor tyrosine kinases (RTKs), which include
fibroblast growth factor receptor (FGFR), vascular endo-
thelial growth factor (VEGFR), Tyrosine-protein kinase kit
(c-KIT), and FMS-like tyrosine kinase 3 (FLT3) [32-35].
According to previous studies, dovitinib exhibits potent
tumor growth inhibition in vitro and in a broad range of
preclinical animal models [32,36-38]. For example, doviti-
nib induced apoptosis in Fibroblast growth factor receptor
(FGFR) expressing mammary cells via inhibition of
Phosphoinositide-3-kinase (PI3K)/Akt signaling path-
way [39]. In addition, dovitinib specifically inhibited
proliferation and survival of primary cells and cell lines
with FGFR1 fusion genes associated with the 8p11 my-
eloproliferative syndrome [40].
There remains a need for not only novel regimens but
also refinement of existing regimens to improve and ex-
tend survival and decrease treatment related toxicities. In
the present study, we hypothesized that Dovitinib may at-
tempt to boost therapeutic kill by employing combination
regimen with oxaliplatin. Our results reveal that co- treat-
ment of Dovitinib and Oxaliplatin in colon cancer cell
lines induced superior cell killing in comparison to either
of these drugs alone in all colon cancer cell lines regard-
less of their mutation status. The significantly enhanced
antitumor activity that results from the combination of
Oxaliplatin and Dovitinib offers promise as a novel treat-
ment for patients with colon cancer. This combination
will achieve a greater anticancer effect at a lower effica-
cious dose with a less chance of a cell developing resist-
ance along with reduced injury to normal cells.
Results
Combination of Dovitinib and Oxaliplatin inhibits cell
viability and migration in colorectal carcinoma cell lines
We performed MTS assay to find out the combined effect
of dovitinib and oxaliplatin in colon cancer cell lines. Sev-
eral human colon cancer cell lines (HCT-116, HT-29,
SW-480, Caco2 and LS174T) were tested for antiprolifera-
tive effects of individual drugs after 72 h of incubation.
Table 1 summarizes the half maximal inhibitory concen-
tration (IC50) values (mean ± standard deviation) and mu-
tation status for different cell lines. All cell lines showed
Table 1 Mutation status and IC50(μM) for Dovitinib and Oxaliplatin in Colon cancer cell lines
Cell Lines HCT-116 HT-29 SW-480 CaCO2 LS174T
Status
Drugs
KRAS M(Gly13Asp) WT M(Gly12Val) WT M(Gly12Asp)
BRAF WT M(Val600Glu) WT M(Val600Glu) WT
PIK3CA/pTEN M WT WT WT M
p53 WT M (273Arg-His) M (273Arg-His M WT
309Pro-ser)
LOH/MSI MSI MSS/LOH MSS/LOH MSS MSI
APC WT M M M WT
Dovitinib 3.050.58 5.21.93 4.330.47 3.230.64 4.330.47
Oxaliplatin 1.670.17 8.02.0 6.02.08 2.70.15 2.871.27
Abbreviations: M Mutant, WT Wild type, LOH Loss of heterozygosity, MSI Microsatellite instability, MSS Microsatellite stable.
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and sensitivity to oxaliplatin varied from 1.6 ± 0.17 μM to
8.0 ± 2.0 μM. HCT-116 cell line showed highest sensitivity
to both the drugs among all five colorectal cancer cell lines
tested. HT-29 cells showed the least sensitivity to both the
drugs probably due to the presence of p-glycoprotein or
multidrug resistance protein efflux pump [41]. These re-
sults are in agreement with previously published IC50
values of dovitinib in breast, bladder and pancreatic can-
cer cell lines and oxaliplatin in colon, breast and pancre-
atic cancer cell lines. Thus, the majority of colon cancer
cell lines revealed sensitivities similar to or slightly better
than most other cancer cell lines. Figure 1A shows the ef-
fect of dovitinib and/or oxaliplatin over real time in HCT-
116, HT-29 and SW-480 cells as recorded by RT-CES
(Real time cell electronic sensor). Both dovitinib and oxali-
platin inhibited the cell growth in HCT-116 and SW-480
cells and insignificant change in HT-29 with either of the
drugs alone. However, the combined effect of dovitinib
and oxaliplatin was more pronounced as compared to ei-
ther of the drugs alone in all cell lines. In HT-29 cells
addition of dovitinib may have sensitized the cells to oxali-
platin. Combination of two drugs added simultaneously
showed better cytotoxicity as compared to sequential
(oxaliplatin-dovitinib or dovitinib-oxaliplatin) addition
(data not shown). The RT-CES data was confirmed by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The com-
bination of dovitinib and/or oxaliplatin in all five colon
cancer cell lines is shown as bar diagram (Figure 1B) and
the calculated combination indices (CI) for the combined
effect is summarized in Figure 1C. Our results show a
strong synergistic effect of the combination despite differ-
ent mutation status among these cell lines. LS-174 T and
HCT-116 showed the strongest synergistic effect of the
dovitinib and oxaliplatin combination in comparison to
HT-29, SW-480 and Caco2 cells.Using the wound healing assay, we next examined the
cancer cell migration in response to mechanical wound.
Figure 1D shows a representative picture of HCT-116,
HT-29 and SW-480 cells in monolayer culture after sub-
ject to mechanical scratch wound injury in the absence
or presence of dovitinib (1 μM) and/or oxaliplatin
(5 μM) before and after 24 h drug treatment. The width
of cell-free wound zone at the end of 24 h post-injury
period was measured and expressed as% of wound width
at 0 h (t0). At the end of 24 h (t24), 86.7% ± 4.7, 76% ±
1.4 and 68.8% ± 12.0 wound was resealed in untreated
HCT-116, HT-29 and SW-480 respectively. Oxaliplatin
showed a significant difference in migration of cells in
HT-29 (50.3% ± 4.3, p < 0.001) when compared to un-
treated cells. Dovitinib treatment alone inhibited the
wound width by approximately 55% (p < 0.001) in HCT-
116 and HT-29 as compared to 75% (p < 0.01) in SW-
480 cells. The combination of dovitinib and oxaliplatin
inhibited cell motility by approximately 75% (p < 0.001)
in HCT-116 and HT-29 cell lines while no additional in-
hibition was observed in combination group in SW-480
cells. Treatment of cultures with two drugs resulted in a
significant inhibition in cell migration compared to un-
treated cultures (Figure 1E).
Combination of Dovitinib and Oxaliplatin inhibits its
cellular targets
To elucidate the underlying mechanism by which com-
bination of oxaliplatin and dovitinib induces inhibition
of proliferation, we examined the alterations in signal
transduction pathway induced by oxaliplatin and/or dovi-
tinib in colorectal cancer cell lines. As stated, dovitinib
has been shown to be a potent inhibitor of receptor tyro-
sine kinases (RTK’s) including FGFR, VEGFR2 and PDGFR.
We determined the overall tyrosine phosphorylation pat-
tern in cell lysates prepared from oxaliplatin and/or doviti-
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Figure 1 Effect of dovitinib and/or oxaliplatin on growth and migration of tumor cells in vitro. Combination of Dovitinib and Oxaliplatin
produce synergistic effect in colon cancer cell lines: (A), Representative Panel of combination effect measured by RT-CES (B), a representative
experiment plotted as histogram showing an effect of oxaliplatin and/or dovitinib in cell viability using MTS assay colon cancer cell lines.
(C) Combination index calculated using Biosoft calcusyn. The values represent Mean ± SEM for at least 3 independent populations measured in triplicates.
(D) Images of migration of cells 24 h after injury in the presence or absence of dovitinib and/or oxaliplatin in colon cancer cell lines. (E), Percentage of
wound closure at 24 h. The graph indicates Mean ± SEM of wound closure at 24 h (n= 3). *P< 0.01. Combination of dovitinib and oxaliplatin inhibits cell
proliferation and migration in colon cancer cells.
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dovitinib inhibited the phosphorylation of several pro-
teins in all three cell lines. Next, we checked the expres-
sion levels of receptors in the presence of oxaliplatin
and/or dovitinib in all three CRC cell lines by western
blot analyses. Only HCT-116 and HT-29 were found to
have expression of both receptors. These two cell lines
showed insignificant changes in the phosphorylation of
FGFR and VEGFR after treatment with either oxaliplatin
or dovitinib while the combination of the drugs showed a
significant down-regulation of phosphorylation of both
the receptors (Figure 2A). Since SW480 cells showed ab-
sence or very low expression most of these receptors, we
checked the effect of the combination on downstream sig-
nalling pathway proteins.
RAS proteins are small GTPases known for their in-
volvement in oncogenesis. Around 25% of human tu-
mors present mutations in a member of this family [42].
Many studies have cleared that activating mutations in
members of the RAS family of genes are among the most
common genetic lesions in human tumors and these
mutations lock RAS proteins into a constitutively acti-
vated state in which they signal to downstream effectors
even in the absence of extracellular stimuli. Involvement
of RAS signaling in cancer is accentuated by the inci-
dence not only of RAS mutations but also the deregula-
tion of many of its regulators or effectors pathways
[43,44]. The first RAS effector pathway to be identified
was the RAF-MEK-ERK pathway [45]. Next, if RAS or
RAF mutations play any role in the response to the
treatment with oxaliplatin and dovitinib, we determined
the expression levels of these proteins in the presence/
absence of these drugs. Irrespective of RAS-RAF muta-
tions, dovitinib inhibited the expression of both RAS
and RAF in all three cell lines tested. The combination
of the two drugs showed an even more pronounced in-
hibition of both RAS and RAF proteins. In addition,
dovitinib inhibited phosphorylation of ERK, a down-
stream signaling molecule of RTKs. These data indicate
that dovitinib inhibits the activity of its target receptors
in tumor cells and results in down modulation of the
signaling pathway (Figure 2B (i) and (iii)).
The second best-characterized RAS effector family is
phosphoinositide 3-kinases (PI3Ks), which play important
roles as mediators of RAS-mediated cell survival and proliferation. When active, PI3K converts phosphatidylinositol
(4, 5)-bisphosphate (PIP2) into phosphatidylinositol (3, 4,
5)-trisphosphate (PIP3). PIP3, in turn, binds the pleckstrin
homology (PH) domain of Akt/PKB, stimulating its kinase
activity, resulting in the phosphorylation of a host of other
proteins that affect cell growth, cell cycle entry, and cell
survival [42,46]. Next, we determined the phosphorylation
of AKT in response to treatment with oxaliplatin and/or
dovitinib. Oxaliplatin or dovitinib produced insignifi-
cant inhibition in AKT phosphorylation in HCT-116
cells, however the phosphorylation decreased signifi-
cantly in combination group as compared to untreated
or either of the treated cells. Dovitinib inhibited the
phosphorylation in HT-29 cells which decreased further
after the combined treatment. SW-480 cells showed a
decrease of phosphorylation in all three treatment groups
(Figure 2B (ii) and (iii)).
Combination of Dovitinib and Oxaliplatin induces DNA
damage
A very early step in the cellular response to chemothera-
peutic drugs is DNA double strand breaks (DSBs) followed
by the phosphorylation of a histone H2A variant, H2AX,
at the site of DNA damage. We determined the extent of
DNA damage by adding oxaliplatin and dovitinib. The
phosphorylation of H2AX increased in HCT-116 cells after
treatment with individual drugs but the combination of
two drugs did not show any additional increase. Oxalipla-
tin or dovitinib alone produced a negligible change in the
phosphorylation status in HT-29 and SW-480 cells, how-
ever, these cells showed a clear increase in phosphorylation
with the combination treatment (Figure 3A (i) and (iii)).
Combination of Dovitinib and Oxaliplatin up-regulates
expression of pro-apoptotic proteins with concomitant
decrease in levels of anti-apoptotic proteins
The pathway leading to induction of apoptosis also in-
volves p53, where p53 may act in association with other
proteins such as Bax (proapoptotic) and Bcl2 family
(antiapoptotic). We next assayed the expression levels of
p53, Bax, Mcl-1, Survivin, Bclxl and Bcl2 in the presence
of oxaliplatin and/or dovitinib. Figure 3A (ii) shows that
treatment of HCT-116, HT-29 and SW-480 cells with
the combination of the two drugs for 24 h up-regulated




























































































































Figure 2 (See legend on next page.)
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Figure 2 Effect of dovitinib and/or oxaliplatin on MAP Kinase and PI3Kinase pathway. Western blot analysis of phosphorylation levels after
treatment with combination of dovitinib and oxaliplatin in colon cancer cell lines. The cells were starved for 24 h followed by treatment with
10 ng/ml FGF for 30 min prior to the addition of either of the drugs for 24 h. (A) Representative protein bands for tyrosine phosphorylation
(py99), p-FGFR and pVEGFR. pFGFR and pVEGFR expression levels were decreased at 24 h after treatment. Coommassie blue (CBB) was used to
show equal protein loading in each lane. (B) Representative protein bands for kRAS, bRAF, pERK, ERK and cMyc (i) and pAKT and total AKT (ii) signaling
pathways. β-actin was used to show equal protein loading in each lane. (iii) Bar diagram (Mean ± SEM) showing the fold change in the intensity of
proteins with respect to b-actin and normalized to untreated group. n = 3; *#+ P < 0.05, vs Untreated, # vs Oxaliplatin and + vs Dovitinib respectively.
Combination of dovitinib and oxaliplatin show more pronounced inhibition in expression of proteins involved in MAP kinase and PI3Kinase pathway.
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in all three colon cancer cell lines when treated with the
combination of oxaliplatin and dovitinib. The effect of
combination was more pronounced in both proapoptotic
and antiapoptotic proteins as compared to either of the
drugs alone. The quantitation intensity of each protein
band in Figure 3A (i) and (ii) with respect to β-actin or
γ-tubulin is shown in Figure 3A (iii).
Combination of Dovitinib and Oxaliplatin induce
apoptosis in colorectal carcinoma cell lines
Through quantitative apoptotic cell death assay, we
assessed whether the observed synergistic cell growth in-
hibition by oxaliplatin-dovitinib combination is accom-
panied by greater apoptotic cell death. Figure 3B shows
combined population of proapoptotic (annexin V positive)
and apoptotic cell (PI positive) population. Oxaliplatin
and dovitinib individually increased the proapoptotic cell
population by 1.8 fold in HCT-116 cells but the combin-
ation increased this number to approximately 3fold. HT-
29 and SW-480 showed no cell death in the presence of
oxaliplatin alone and only marginal increase in annexin
positive cells with dovitinib. However, the combination of
two drugs increased this number to 1.6 and 2.2 fold in
HT-29 and SW-480 cell respectively. Combination of oxa-
liplatin and dovitinib increased the PI positive cell popula-
tion by 1.5 to 1.8 fold (p = 0.05) as compared to untreated
cells in all three colon cancer cell lines tested.
To study the mechanistic aspects of apoptosis induction
by the combination of oxaliplatin and dovitinib, we next
assessed the activation of caspases by Western blot ana-
lysis. Although treatment with oxaliplatin or dovitinib
alone increased the levels of cleaved caspase-9 and −3 in
all three cell lines tested, the increase was more amplified
with the combination of the two drugs indicating the
involvement of these caspases in apoptosis induction
(Figure 3Ci). An important factor in inducing apoptosis is
the enzyme Poly (AD ribose) polymerase (PARP) that de-
tects DNA strand breaks and functions in base excision
repair. Once PARP is cleaved, it no longer supports the
enzymatic DNA repair function. It is a known marker of
apoptosis and a downstream target of activated caspase-3
[47]. The expression of cleaved PARP was greatly en-
hanced after the treatment of HCT-116, HT-29 and SW-480 cells with combination of oxaliplatin and dovitinib,
which might have contributed to the commitment to
apoptosis (Figure 3C (i)). The quantitation intensity of
PARP with respect to β-actin is shown in Figure 3C (ii).
Combination of Dovitinib and Oxaliplatin inhibits tumor
growth in Human Colorectal Cancer HT-29 Xenograft
Based on our results showing strong efficacy of the com-
bination of oxaliplatin and dovitinib in colorectal cancer
cells in culture, next we examined the in vivo efficacy of
the combination against the colorectal cancer HT-29 xeno-
graft in athymic nude mice. Figure 1A (i) shows tumor
growth curve after treatment with oxaliplatin and/or
Dovitinib. Treatment with 3 weekly doses of oxaliplatin
(day 11, 18, and 25) at 6.7 mg/Kg was inactive as mono-
therapy in all animals. This is in agreement with a study
showing inactivity of oxaliplatin as monotherapy in HT-29
animal model at MTD of 10 mg/Kg [48]. Similarly an al-
ternate day dose of 60 mg/Kg Dovitinib showed a decrease
of tumor growth as early as day 4 after treatment in all an-
imals. The combination of two drugs showed a significant
decrease (p < 0.05) in tumor growth stating from an early
stage as compared to vehicle or oxaliplatin treatment
while at late stage compared to dovitinib alone. Similar re-
sults were also observed by Lee et al. in KM12L4a and
HCT-116 colon cancer tumor models at dose level of 30-
100 mg/Kg [32]. The average final tumor volume was re-
duced from 2,036 ± 327.5 mm3 in control group to 1,957 ±
204.0 and 1,415 ± 205.9 mm3 in oxaliplatin and dovitinib
treatment groups respectively, accounting for only 4% de-
crease in oxaliplatin group and 31% (P < 0.001; Figure 4A
(ii)) decrease in dovitinib treatment group at the end of the
experimental period. However, the combination treatment
group showed a tumor volume of 906 ± 94.8 mm3, an ap-
proximate 55% decrease in tumor volume from vehicle or
oxaliplatin group and 36% decrease from dovitinib treat-
ment group. Tumor growth delay and doubling time (DT)
of tumor volume of each group was calculated from a
Log-linear growth plot (Figure 4B). The tumor growth
delay was calculated as the time difference between each
treatment group and the control group when the average
tumor size reached 1000 mm3. Combination treatment
with oxaliplatin and/or dovitinib did not show any gross

































































































































































































Figure 3 (See legend on next page.)
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Figure 3 Effect of dovitinib and/or oxaliplatin onset of tumor cell apoptosis and caspases activation. Western blot analysis of DNA
damage and proteins involved in apoptotic pathway after treatment with combination of dovitinib and oxaliplatin in colon cancer cell lines (A)
Expression of γH2AX (i) and p53, BAX, Blc-2, Bclxl, Mcl-1 and survivin at 24 h after treatment (ii). γ-tubulin or β-actin was used to show equal protein
loading of each lane. (iii) Bar diagram (Mean ± SEM) showing the fold change in the intensity of proteins with respect to β-actin or γ-tubulin and
normalized to untreated group. n = 3; *#+ P < 0.05, vs Untreated, # vs Oxaliplatin and + vs Dovitinib respectively. (B) Cell cycle analysis: approximately
one million cells before and after treatment with dovitinib and/or oxaliplatin for 48 h. Cells were harvested, stained with annexin V–FITC and/or
propidium iodide and subjected to flow cytometric analysis. The percentage of annexin V–FITC positive cells were determined by calculating the ratio
to the total number of cells. Each bar represents the Mean ± SEM of at least three independent experiments, *p < 0.05. (C) Induction of caspases
cascade and PARP after treatment with dovitinib and/ or oxaliplatin (i). Bar diagram (Mean ± SEM) showing the fold change in the intensity of cleaved
PARP with respect to β-actin and normalized to untreated group. n = 3; * P < 0.05 (ii). Combination of dovitinib and oxaliplatin show up-regulation of
proapoptotic and down-regulation of antiapoptotic proteins via caspases dependent apoptotic pathway.
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consumption. Also, the necropsy report showed no abnor-
mality in these mice at the end of the experiment. Reports
have shown that Dovitinib as high as 120 mg/Kg for con-
tinuous 25 days exerted no toxicity in animals [32].
In an attempt to understand some of the details of the
mechanism of action of combination, the tumors were
removed from mice and processed for immunohistochem-
ical expression of Ki-67 and CD-31. Ki-67 antigen is the
prototypic cell cycle related nuclear protein, expressed by
proliferating cells in all phases of the active cell cycle and
absent in resting cells. It is routinely used as a marker for
proliferating cells. Representative photomicrographs of
Ki-67 antigen–stained sections from untreated, oxaliplatin
and/or dovitinib tumors are shown in Figures 4C (i) a-d.
Staining for Ki-67 decreased immensely with the treat-
ment of oxaliplatin combined with dovitinib compared to
untreated tumors as well as either of oxaliplatin or doviti-
nib administered groups.
Angiogenesis is crucial for tumor development and
CD31 is widely used as a marker to highlight the density
of intra-tumoral vessels and the degree of neoangiogen-
esis. Its immunoexpression was mainly localized in the
junction between cells and is clearly positive in tumors
from the vehicle control group with slight inhibition in the
oxaliplatin and dovitinib treated tumors and almost negli-
gible staining in combination treatment group (Figure 4C
(ii) a-d). Figures 4C (iii) a-d show the H & E staining in tu-
mors from all the groups. The quantitative data for immu-
nostaining is shown in Figure 4D.
These results suggest an in vivo antitumor efficacy of
the combination against colorectal cancer without any ap-
parent signs of toxicity. Also, antitumor effect of the com-
bination of oxaliplatin and dovitinib is due to inhibition of
both proliferation and angiogenesis.
Discussion
In this study, we evaluated the growth inhibitory effects
of dovitinib and oxaliplatin combination in cell culture
and xenograft models of colon cancer, and our goal for
this investigation was to elucidate potential molecular
mechanisms of action for the compounds contributingto the antiproliferative and anticancer capacity of human
colon cancer cells. We found that both oxaliplatin and
dovitinib (in the low micromolar range) effectively di-
minished the growth of colon cancer cell lines regardless
of their RAS-RAF mutation status (Figure 1). Of greater
interest, we found that this combination showed a syner-
gistic antiproliferative activity and inhibition of angio-
genesis in a colon cancer xenograft model with a bRAF
mutation and multi drug resistant phenotype (Figure 4).
Initiation and progression of colorectal carcinoma is
defined by abnormally high activation of RAS-RAF sig-
naling pathway controlled by tyrosine kinases [18-20].
Activated forms of tyrosine kinases such as VEGFR,
FGFR and PDGFR are known to play role in tumor
angiogenesis, a process essential for growth of tumors.
[22]. These receptors are activated by their correspond-
ing growth factors secreted by tumor cells resulting in
proliferation, migration and survival of tumor endothe-
lial cells [49]. Although VEGF RTKs are the major tar-
gets for dovitinib, preclinical studies have also shown
that FGF signaling is a possible mechanism of escape
from and resistance to anti-VEGF therapy [50]. There-
fore, dovitinib’s uniqueness in inhibiting growth factor
receptors including FGFR and VEGFR makes it stand
out among other RTKs inhibitors. A high percentage of
colorectal carcinomas over-express a lot of growth fac-
tors and their receptors, including fibroblast growth fac-
tor (FGF) and FGF receptor (FGFR) [51]. Takayama
et al. have shown that over-expression of FGFR corre-
lates with liver metastasis in CRC [52]. Our results
showed a decrease in phosphorylation of VEGFR and
FGFR in two colon cancer cell lines tested. In vitro data
in HCT116, HT-29 and SW-480 cell lines showed de-
creases in expression of all proteins in MAP kinase path-
way such as kRAS, bRAF and pERK. Previous studies
have shown that use of MEK inhibitors impaired prolif-
eration thereby impacting a diverse array of cellular
events, including differentiation, apoptosis, and angio-
genesis [53]. However, Turke et al. have shown that
MEK inhibitor led to activation of a parallel PI3K/AKT
signaling pathway involving several feedback systems
[54]. The vice versa has also been shown true in which
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Figure 4 The antitumor effect of dovitinib and/or oxaliplatin on the xenograft of colon cancer. Treatment with dovitinib and oxaliplatin
significantly decrease the growth of HT29 colon cancer xenografts in athymic mice. In these experiments, mice were treated with 60 mg/kg
dovitinib (oral/2 days) and/ or 6.7 mg/kg oxaliplatin (i.v., once/week). Matched control mice bearing xenografts received an equal volume of
saline on the same treatment schedule. Significance was determined using a two-way ANOVA. (Ai) Tumor volume changes after administration
of drugs. (Aii) Bar diagram (Mean ± SEM) showing the tumor volume on day 28 after the treatment, n = 10; *P < 0.05 and #p < 0.01. (B) Tumor
growth delay in various treatment groups calculated from a Log-linear growth plot. (C) Representative panel of immunohistochemical analysis of
(i) Ki-67 and (ii) CD-31 (cluster of differentiation molecule also known as PECAM-1) in tumors extracted from mice with/without treatment with
dovitinib and/or oxaliplatin. Magnification (10×) with inset at (40×). (iii) H & E staining of corresponding sections from untreated and treated
tumors. (D) Bar diagram (Mean ± SEM) showing the quantitation of average number of Ki-67 positive cells and CD-31 positive vessels as
percentage of saline treated control, n = 10; * P < 0.05. Combination of dovitinib and oxaliplatin inhibits the tumor growth by inhibition of
cell proliferation and angiogenesis.
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way [55], thereby decreasing the effectiveness of single-
agent targeted therapies. This suggests that concomitant
inhibition of both pathways is necessary to block prolif-
eration and induce cell death and shrink the tumor.
Since inhibition by dovitinib in these cell lines was an
upstream of kRAS, a parallel inhibition of both RAS-
RAF-MAPK and PI3K-AKT suggest a synergistic effect
of both pathways on downstream effectors of growth
and proliferation. Our data also showed an inhibition of
expression of pAKT in all three cell lines. Our results
are in agreement with a recent report showing a con-
comitant down-regulation of PI3K and MEK induced re-
gression of kRAS mutant cancers in vivo [56].
Our results with wound healing assay showed a signifi-
cant decrease in wound repair with the use of combin-
ation of two as compared to either of the drugs alone
confirmed a simultaneous inhibition of both signaling
pathways (MAP Kinase and PI3Kinase) which are known
to contribute to the inhibition of protein synthesis, cell
growth, proliferation and survival. Lee et al. have shown
that inhibition of FGFR and PDGFR starts as early as
4 h in the presence of Dovitinib [32].
A phase 1 pharmacokinetic and pharmacodynamic study
of dovitinib in patients with advanced solid tumors showed
a dose limiting toxicity of grade 3 hypertension and fatigue
[57]. The strategy to improve the efficacy of the therapy
and alleviate the symptom burden without increasing the
toxicity is to add chemotherapeutic drug. In clinical stud-
ies, Oxaliplatin by itself has shown modest activity against
advanced colorectal cancer. It has been extensively studied
in combination with 5-FU and Folinic Acid. Our results
demonstrate that when combined with dovitinib it showed
a synergistic cytotoxicity by inducing apoptosis in colon
cancer cell lines tested. There is compelling evidence that
defects in apoptosis contributes to cancer. The molecular
mechanism showed an increase in phosphorylation of
histone H2AX at serine 139 in response to DNA double
strand break by oxaliplatin. This DNA damage activated
and stabilized p53, in turn, regulating the apoptotic
pathway. It has been demonstrated many times that ac-
tivation of p53 by DNA damage can lead to apoptosis bytranscriptional activation of pro-apoptotic members of
Bcl-2 family (Bax and Bak) and inhibition of anti-apoptotic
(Puma, Noxa, Bcl2, Bclxl, Mcl-1 etc.) proteins, which
together regulate mitochondrial permeability [58-60].
Also, it has been reported that AKT directly regulates
members of the Bcl-2 super family and indirectly regulates
apoptosis through the transcriptional factors that control
apoptotic events [61]. Our results demonstrated an up-
regulation of Bax and down-regulation of Bcl2 and Bclxl
after treatment with the combination of oxaliplatin and
dovitinib. The combination showed a more pronounced
effect than either of the drugs alone. Mcl-1 a member of
Bcl2 family and an inhibitor of apoptosis, showed a signifi-
cantly higher expression in colon adenoma and carcinoma
patient compared to healthy colonic epithelium [62]. Also,
it has been shown that sustained activation of Akt resulted
in increased expression of the antiapoptotic protein, Mcl-
1 [63]. Our results showed a significant decrease in the ex-
pression of Mcl-1 after treatment with dovitinib possibly
through the inactivation of AKT kinase. The expression
was further reduced in the combination group in all three
cell lines tested. Survivin is another molecule described to
be involved in both the control of cell survival and regula-
tion of cell cycle. Dramatic over-expression of Survivin
compared with normal tissue has been shown in different
kinds of cancer (reviewed in [64]). Survivin is also known
to inhibit apoptosis mainly through targeting terminal ef-
fector caspase 3 activity in the apoptotic protease cascade
[65]. Caspases are proteins known to be involved in the
cascade of initiation and execution of apoptosis. Our re-
sults showed a decrease in Survivin after treatment with
dovitinib and/or oxaliplatin in all cell lines. The com-
bination treatment also showed a decrease in expression
of procaspase 3, 8 and 9 with a subsequent increase in
cleaved caspases. Our data also show a decrease and in-
crease in expression of PARP and cleaved PARP respect-
ively, a downstream target of activated caspase-3.
In parallel, in vivo results showed an inhibition of tumor
growth in HT-29 tumor model with coordinating decrease
in the expression of Ki-67 (biomarker for proliferation)
and CD31 (biomarker for angiogenesis). The decrease was
more pronounced in the combination group as compared
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the combination inhibited angiogenesis which correlates
to slow tumor growth supposedly because of lack of fac-
tors that are supplied through blood, thereby inhibiting
the tumor growth. Our results are in agreement with
previous reports showing inhibition of expression of Ki-
67 and CD31 correlating to the shrinking of tumors and
overall disease free survival [66,67].
Conclusions
Our results provide compelling evidence that dovitinib
in combination with oxaliplatin inhibits cell growth and
induces apoptosis in colon cancer cell lines. Simultaneous
targeting of both MAP kinase and PI3Kinase by dovitinib
to inhibit cell proliferation and induction of cell death
through caspase dependent pathway by oxaliplatin con-
tributes to the synergistic decrease in cell proliferation
and viability. Furthermore, combined treatment with
the two drugs effectively reduced growth of xenografted
HT29 cells grown in athymic mice without exhibiting
any toxicity in the animals. This antitumor efficacy of
the combination was due to the inhibition of cell prolif-
eration accompanied with suppression of angiogenesis.
Schematic representation of our hypothesis is shown in
Figure 5. In summary, combination of dovitinib and
oxaliplatin produced a synergistic effect in colon cancer
cells regardless of their RAS-RAF/p53 mutation status
and also in a multidrug resistant clone of colon cancerFigure 5 A working model for the synergistic effect of dovitinib and/
inhibition of MAPK and PI3Kinase signaling pathways by dovitinib and DNA




Human colon cancer cell lines HCT-116, HT-29, SW-480,
Caco2 and LS-174 T were purchased from American
Type Culture Collection (Manassas, VA). Cell culture
media and serum were obtained from Invitrogen Life
Technologies (Carlsbad, CA). Dovitinib (TKI-258) was ob-
tained from Novartis (East Hanover, NJ) and Oxaliplatin
was obtained from Sigma-Aldrich (St. Louis, MO). Anti-
bodies against different proteins were obtained from
Santacruz Biotechnologies Inc. (Santacruz, CA) or Cell
signaling technology Inc. (Beverley, MA). HRP Conju-
gated anti-mouse IgG and Enhanced chemilumines-
cence plus (ECL plus) western blotting detection
reagent were purchased from Amersham Bioscience
(Arlington Heights, IL), X-OMAT AR films (Eastman
Kodak, Rochester, NY). All other reagents were ob-
tained from Fisher Scientific (Pittsburg, PA).
Cell culture
The tumor cell lines were maintained in culture as adher-
ent cells in a monolayer in humidified atmosphere at 37°C
and 5% CO2 in McCoy’s 5A (HCT-116 and HT-29),
Leibovitz’s L-15 Medium (SW-480), and Eagle’s Minimum
Essential Medium (Caco2 and LS-174 T) and supplementedor oxaliplatin on tumor cells. We propose that simultaneous
damage by oxaliplatin play an essential role in regulating apoptosis
genesis and inhibition of colon cancer cell proliferation.
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The cells were passaged twice a week and discarded after
20 passages.Cell viability assay
The cell viability was measured using MTS assay as de-
scribed earlier [68]. IC50 values were calculated from the
dose response curve generated from the colon cancer
cell lines in the absence or presence of the drug(s). A
real-time cell electronic sensing (RT-CES, ACEA Biosci-
ences Inc., San Diego, CA) system was also used for
measurement of cell response for combination of doviti-
nib and oxaliplatin in HCT-116, HT-29 and SW-480 cell
lines. Briefly, 5000 cells were grown onto the surface of
microelectronic sensors in a 16-well plate supplied by
the manufacturer. After 24 h, a wide range of concentra-
tions of drugs were added and the cells were continu-
ously monitored by the system. The experiments were
repeated with comparison of simultaneous and sequen-
tial addition of the two drugs. These results were further
confirmed using MTS assay. Briefly, for combination ex-
periments the drugs were mixed in 1:1 ratio of IC50 con-
centration or maximum achievable dosage and diluted
to ½ and ¼ concentrations before the addition to the
cells. Data from cell viability assay (MTS) were ex-
pressed as the fraction of cells killed by the individual
drugs or the combination of drugs and compared to un-
treated cells.Determination of Synergism
The interaction between drug combinations was analyzed
using Calcusyn software program (Biosoft, Cambridge, UK)
to determine whether the combination was additive
or synergistic. This program is based on Chou-Talalay
method and calculates a combination index (CI), when
CI =1, it indicates an additive effect and when below 1.0,
it indicates synergism.Wound-healing assay
Cells were plated in 24-well plates and grown to conflu-
ence. The monolayer was wounded using the tip of a
sterile 200 μl pipette. Cell debris was removed by wash-
ing twice with serum-free medium and replacing with
medium containing serum and Dovitinib and/or Oxalipla-
tin. Cells were then allowed to migrate into the denuded
areas for 24 hr. Photographs were taken immediately after
wounding (t0) and 24 hr later (t24) using the Leica
DMI3000 B inverted microscope. The results were quanti-
fied as a percentage of the wound width closed by the cells
at time 24 hr (T24 = (100/t0)/t24). The mean of three ex-
periments was graphed with standard deviations repre-
sented as error bars.Western blot analysis
Cells were collected after 24 h treatment with dovitinib
and oxaliplatin and washed once with PBS and second
time with cold PBS containing 0.1 mM orthovanadate.
The whole cell lysates were prepared according to the pro-
cedures described previously [68]. Protein was measured
using Bio-Rad protein assay kit (Bio-Rad, Hercules, CA)
and. The proteins were transferred to PVDF membrane
(Amersham, Arlington Heights, IL) after resolving by
(25 μg protein per lane) 4-12% gel electrophoresis (SDS-
PAGE) and probed with one of the following: RAS, RAF,
p-ERK, ERK, p-AKT, AKT, Survivin, Caspase 3, Caspase
9 (Cell signaling technology, Boston, MA), p53, Anti-
phosphotyrosine (4G10), γH2AX and pATM, β-actin
(EMD Millipore, Billerica, MA ), p21, Bax, Bcl-2, Bclxl,
Mcl-1, cytochrome C, c-Myc (Santa Cruz biotechnol-
ogy, Santacruz, CA), GAPDH (GeneTex, Irvine, CA)
and Cleaved PARP (Promega, Madison, WI) antibodies
and HRP conjugated secondary antibody (Amersham).
The optical density for each band was determined using
Image Quant software (GE Healthcare Biosciences,
Pittsburg, PA).
Apoptotic cell death assay
To quantify apoptosis, HCT-116, HT-29 and SW-480
cells were stained with annexin V and PI using FITC
Annexin V Apoptosis detection kit 1 from BD Pharmin-
gen following the step by step protocol as provided by
the manufacturer and analyzed by flow cytometry (BD
Bioscience, San Diego, CA). Briefly, at the end of treat-
ment with dovitinib and oxaliplatin either alone or in
combination for 48 h, both floating and attached cells
were collected, washed twice with cold PBS and sub-
jected to annexin V-FITC and PI staining and analyzed
using flow cytometry.
Subcutaneous human tumor xenograft
In vivo evaluation of Dovitinib and/or Oxaliplatin in
HT-29 human colorectal cancer model was performed
at Institute of Translational Medicine, Taipai Medical
University (TMU), Taipei, Taiwan.
Animal
Forty female athymic nude mice (BALB/cAnN.Cg-Foxn1nu/
CrlNarl; 5 weeks of age) were purchased from the NAR
Labs National Laboratory Animal Center (Taipei, Taiwan).
Mice were housed in TMU Laboratory Animal Center
(Taipei, Taiwan) around a specific pathogen-free animal
facility at constant temperature (20 ± 3°C) and humidity
(50 ± 20%). The animals had free access to irradiation-
sterilized dry granule food and water during the study
period. Animal care and the treatment were performed ac-
cording to the guidelines of the Institutional Animal Care
and Use Committee (IACUC) based on guidance of the
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tory Animal Care (AAALAC).
Cell culture
HT-29 tumor cells were maintained in vitro in McCoy’s
5A medium supplemented with 10% FBS and 0.1 mM
NEAA. The cells growing in exponential growth phase
were harvested and counted for tumor inoculation.
Tumor inoculation
Each mouse was inoculated subcutaneously at the rear
right flank with HT29 tumor cells (3 × 105) in 0.1 ml of
PBS for tumor development. After 10 days of tumor in-
oculation, the animals were weighed and measured for
tumor volume and randomly divided into 4 groups of 10
animals each based on the randomized block design
method for homogeneous group formation when the
mean tumor size reached approximately 80–125 mm3
(10 Days).
Drug treatment
The treatment was started intravenously (i.v.) on the
11th day post tumor inoculation with 0.9% saline (Group 1),
6.7 mg/Kg Oxaliplatin (Group 2), 60 mg/Kg Dovitinib
(Group 3) and 6.7 and 60 mg/Kg Oxaliplatin and Dovitinib
(Group 4) respectively. The treatment was continued for
3 weeks with a regimen of once per week (i.v.) for Oxali-
platin and every two days (oral) for Dovitinib.
Tumor measurement
The animals were visually monitored for food and water
consumption everyday and once/week for body weight
(gain/loss) and tumor size. Tumor volumes were calculated
using formula: V = 0.5 × a × b2 where a and b are the long
and short tumor diameters respectively and euthanized
when the tumor volume reached a predetermined size of
approximately 3000 mm3. This end-point tumor size was
chosen to maximize the number of tumor doublings within
the exponential growth phase in the untreated group. All
the tumors were harvested a week after the last treatment
and fast frozen for immunohistochemistry.
Tissue preparation and immunohistochemical staining
The immunohisto-chemical assays were performed using
a Dako Autostainer Plus (Dako Colorado Inc., CO) with
fresh sections of vehicle control and treated tissue stained
at the same time with the help of research pathology core
facility at the City of Hope as described in [69]. Primary
rabbit Ki67 (Novus Biologicals) or mouse monoclonal
CD31 antibody (Cell Marque, CA) were used for IHC at a
final concentration of 1:100(Ki-67) or 1:75 (CD31). The
sections were counterstained with Meyer’s haematoxylin
and each run also included phosphate buffered solution
(PBS) used as the primary antibody for the negativecontrols while samples known to express Ki-67 or CD31
strongly served as positive controls. Photomicrographs
were taken on a Nikon microscope equipped with a
CCD camera.Statistical analysis
Data points for cell proliferation and apoptosis were pre-
sented as mean ± standard error mean of at least three
independent cell populations. Results were compared
using two-tailed student’s t-test using Microsoft Excel
Program 2003. A p-value <0.05 was considered statisti-
cally significant. Animal data results were compared
using student’s t-test. Animal study data were evaluated
using one-way ANOVA followed by Dunnett’s post-test
if significance was observed. The data were analyzed
using SPSS version 16.0. A p-value <0.05 was considered
statistically significant.
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